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Abstract 
Background: Atrial fibrillation (AF) is associated with cognitive decline and may contribute 
to an increased risk of dementia. The goal of the present study was to investigate whether 
statin use prevented non-vascular dementia in subjects with AF. 
Methods: Data from the National Health Insurance Research Database of Taiwan were used 
in this study. The study group comprised 51,253 AF subjects aged > 60 years who had 
received statin treatment. For each study patient, four age- and sex-matched AF subjects 
without statin exposure were selected as the control group (n = 205,012). The risk of non-
vascular dementia was compared between the statin and control groups.  
Results: During the follow-up period, 17,201 patients experienced non-vascular dementia. 
The annual incidence of non-vascular dementia was lower in the statin group than in the 
control group (1.89% vs. 2.20%; p < 0.001). Statin use exhibited a protective effect on the 
occurrence of non-vascular dementia, with an adjusted hazard ratio (HR) of 0.832 (95% 
confidence interval = 0.801–0.864). Among statin types, the use of rosuvastatin was 
associated with the largest risk reduction (adjusted HR = 0.661). Statin exposure duration 
was related inversely to the risk of non-vascular dementia.  
Conclusions: In this large-scale nationwide cohort study, statin use was associated with a 
lower risk of non-vascular dementia in AF. Use of more potent statin and longer exposure 
time may be associated with greater benefits. 
Key words: atrial fibrillation, statin, dementia 
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia; its prevalence 
increases steadily with age and it affects up to 9% of the population aged > 80 years.
1
 
Worldwide, the number of people aged ≥ 65 years will reach 1.3 billion by 2040,2 and the 
incidence of AF is projected to rise continuously over the next few decades due to the aging 
of the population.
3,4
 Similar to AF, the prevalence of dementia, a disorder characterized by 
memory and cognitive impairments, also increases with age. Recent evidence has 
demonstrated that AF is associated with an increased risk of cognitive and functional decline 
and may contribute to the risk of dementia.
2,5-7
 In a meta-analysis of eight studies including 
77,668 patients, Santangeli et al reported that AF increased the risk of incident dementia by 
42%.
7
 Thus, how to prevent the occurrence of dementia in patients with AF is an interesting 
and important issue. 
It is generally believed that statins have pleiotropic effects beyond their lipid-lowering 
activities. The potential benefits of statin use in preventing dementia was first reported in 
2000, when two epidemiologic studies reported a lower risk of dementia in statin users.
8,9
 
Although several subsequent studies reported inconsistent results,
10-13
 a recently published 
meta-analysis that pooled data from eight long-term studies demonstrated a 29% reduction in 
incident dementia in statin-treated patients.
14
 As these previous studies did not focus on the 
population of patients with AF, whether the use of statin can reduce the risk of dementia in 
these patients remains unknown.  
The objective of the present study was to investigate whether statin use was associated 
with a lower risk of incident dementia in patients with AF. We tested the hypothesis that 
statin use would result in less dementia, and second, this would be related to use of more 
potent statins and longer statin exposure duration. 
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Methods 
Database 
Data from the National Health Insurance Research Database (NHIRD), released by the 
Taiwan National Health Research Institutes, were used in this study. The National Health 
Insurance (NHI) system is a mandatory universal program that offers comprehensive medical 
care coverage to all Taiwanese residents. The NHIRD contains detailed health care data from 
>25 million enrollees, representing >99% of Taiwan’s population. In this cohort dataset, the 
patients’ original identification numbers have been encrypted to protect their privacy, but the 
encryption procedure was consistent, allowing linkage of claims belonging to the same 
patient within the NHI database and continuous following of patients. The large sample size 
of this database provided a good opportunity to study the association between statin use and 
incident dementia in patients with AF. 
Study population and definition of study endpoint 
The records of 292,029 patients aged ≥ 60 years who were newly diagnosed with AF 
between 1 January 1996 and 31 December 2011 were retrieved from the NHIRD. AF was 
diagnosed using the International Classification of Diseases, 9th revision, clinical 
modification (ICD-9-CM) codes (427.31). To ensure the accuracy of diagnosis, only patients 
whose AF was confirmed more than twice in the outpatient department or diagnosed at 
discharge were included in the AF cohort.
15
 The diagnostic accuracy of AF using this 
definition in NHIRD has been validated previously.
16,17
 Each patient’s prescriptions for 
statins available in Taiwan were identified. These drugs included atorvastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin and simvastatin. Among the AF cohort, 51,253 subjects 
who had continuously received statins for >30 days and had no past history of dementia 
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(ICD-9-CM codes 290.0–290.3, 290.4, 294.1x, 294.2x, and 331.0) were identified as the 
study group (statin users). We defined the date of statin prescription, when each study subject 
was identified, to be the index date. On the same index date of one study patient, four age- 
and sex-matched subjects without statin exposure were selected for each included study 
patient to constitute the control group. The duration between the diagnosis of AF and index 
date was defined as the “AF duration”. 
The study endpoint was the occurrence of non-vascular dementia, including pre-senile 
and senile dementia  (ICD-9-CM codes 290.0–290.3) and Alzheimer’s disease (ICD-9-CM 
code 331.0).
18
 Vascular dementia (ICD-9-CM code 290.4) was not defined as the study 
endpoint. All subjects were followed until the study endpoint or for 10 years after enrollment. 
For each patient in the statin group, the duration of exposure (days) to each type of statin 
from the time of enrollment to the study endpoint or the end of follow up was calculated. The 
dominant type of statin treatment was determined based on the longest duration of exposure. 
The total duration of exposure to statins was defined as the sum of the durations of all statin 
usages during the follow-up period. 
Statistical analysis 
Data are presented as mean values and standard deviations for normally distributed 
continuous variables, medians and interquartile ranges for skewed data, and proportions for 
categorical variables. The differences between normally distributed continuous values were 
assessed using unpaired two-tailed t-tests. The Mann–Whitney rank-sum test was used for the 
analysis of skewed variables, and the differences between nominal variables were compared 
with the chi-squared test. The risk of non-vascular dementia was assessed using Cox 
regression analysis. An event-free survival curve was plotted using the Kaplan–Meier method 
with the time zero setting at the index date, and its statistical significance was examined 
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using the log-rank test. All statistical significance levels were set at p < 0.05 and all statistical 
analyses were performed using SPSS software (ver. 17.0; SPSS Inc., Chicago, IL, USA). 
Results 
Baseline characteristics of patients 
The mean age of the study population was 73.2 ± 7.4 years, and 49.7% of patients were 
men. Hypertension was the most prevalent comorbidity, noted in 92.5% of patients. Baseline 
characteristics of the statin and control groups are shown in Table 1. Patient age, sex, and 
CHA2DS2-VASc score were matched between the statin and control groups. Patients in the 
statin-users group had more comorbidities, including diabetes mellitus, previous vascular 
diseases, end-stage renal disease, chronic obstructive pulmonary disease, autoimmune 
diseases, thyroid diseases, and sleep apnea, than controls. In contrast, hypertension, 
congestive heart failure, and liver cirrhosis were more prevalent in the control group. More 
patients in the statin group than in the control group took aspirin, clopidogrel, warfarin, and 
angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. Digoxin was more 
commonly used in the control group than in the statin group. 
Statins and the risk of non-vascular dementia 
During the follow-up period, 17,201 (6.7%) patients developed incident non-vascular 
dementia. The annual incidence of non-vascular dementia was lower in the statin-users group 
than in the control group (1.89% vs. 2.20%; p < 0.001; Table 2).  Kaplan–Meier survival 
analysis showed that statin use was associated with a lower risk of incident dementia during 
the follow-up period (Figure 1). Statin use exhibited a protective effect on the occurrence of 
non-vascular dementia, with a hazard ratio (HR) of 0.856 (95% confidence interval [CI] = 
0.824–0.889; p < 0.001) in the univariate regression analysis. After adjustment for age, 
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gender, and differences in baseline characteristics, the HR was 0.832 (95% CI = 0.801–0.864; 
p < 0.001) (Table 3). In the subgroup analysis, statin use was consistently associated with a 
lower risk of dementia in different groups of patients (Figure 2). Among patients without 
previous history of stroke/transient ischemic attack and did not experience stroke during the 
follow-up period (n = 109,697), the risk of non-vascular dementia was lower in the statin 
group with a HR of 0.831 (95% CI = 0.795-0.909, p <0.001). 
Although the use of anti-thrombotic agents, including warfarin, aspirin and clopidogrel, 
were significantly different between study and control groups, the risk of dementia was still 
lower in the statin group for patients without use of these anti-thrombotic drugs (n = 116,727) 
with an adjusted HR of 0.844 (95% CI = 0.795-0.896, p <0.001)(Figure 2).  
Sensitivity analysis 
Among the 17,201 patients suffering non-vascular dementia, the diagnoses were made 
or confirmed by neurologists and psychologists in 8,770 (51.0%) subjects, and 12,820 (74.5%) 
patients had brain imaging studies, including a computed tomography scan or magnetic 
resonance imaging. When the study endpoint was defined as non-vascular dementia 
diagnosed or confirmed by neurologists and psychologists, statin use was still associated with 
a lower risk of non-vascular dementia with an adjusted HR of 0.781 (95% CI = 0.739-0.824; 
p <0.001) after adjustment for age, gender, and differences in baseline characteristics. When 
brain imaging studies were required for the diagnosis of study endpoint in addition to being 
confirmed by neurologists and psychologists, the risk of non-vascular dementia was also 
consistently lower in the statin group with an adjusted HR of 0.817 (95% CI  = 0.769-0.869; 
p <0.001). When patients who experienced stroke within 1 year before the non-vascular 
dementia was diagnosed (n = 688) were further excluded from the clinical endpoint, the HR 
of non-vascular dementia for statin group was 0.847 (95% CI = 0.798-0.900, p <0.001). 
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Types of statin, exposure duration, and the risk of non-vascular dementia 
In a subgroup analysis of the different types of statin, rosuvastatin was associated with 
the largest (34%) relative risk reduction for incident dementia, with an adjusted HR of 0.661 
(95% CI = 0.602–0.727; p < 0.001; Figure 3A). Conversely, fluvastatin and lovastatin 
exhibited no significant protective effect on the occurrence of non-vascular dementia (Figure 
3A). We further divided statin users (n = 51,253) into four groups based on quartile values of 
statin exposure duration and compared the risk of non-vascular dementia among these groups, 
with the first quartile group serving as the reference population. As shown in Figure 3B, the 
risk of non-vascular dementia decreased with increasing duration of statin exposure. 
Propensity-matched analysis 
Because statin and control groups have different baseline characteristics, we performed 
a propensity score–matched analysis, in which we calculated a propensity score for the 
likelihood of using statins by multivariate logistic regression analysis, conditional on the 
baseline covariates listed in Table 1. After that, we matched each study patient to a control 
participant on the basis of age, gender, and propensity score (±0.01). The results of the 
propensity score model about the probability of the use of statins were shown in 
Supplemental Table 1.  Supplemental Figure 1 showed the distributions of propensity scores 
of study subjects before and after the propensity match. Baseline characteristics of the statin 
and control groups after propensity match were shown in Supplemental Table 2. Age, gender, 
comorbidities and medications were not statistically different between patients with and 
without statin exposure. The risk of non-vascular dementia was significantly lower in the 
statin group than that of the control group, as demonstrated by the Kaplan–Meier survival 
analysis (log-rank test, p<0.0001) (Supplemental Figure 2). 
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Discussion 
Main findings 
In this nationwide cohort study, we compared the risk of non-vascular dementia in statin 
users and non-users with AF. The main findings were: (1) Statin use may play a role in 
preventing incident non-vascular dementia, with a 17% risk reduction in patients with AF 
aged ≥ 60 years. The association between stain use and a lower risk of dementia was 
observed consistently in propensity-matched cohorts and when several sensitiviy analyses 
with different criterions required to define non-vascular dementia were performed. (2) A 
potent statin such as rosuvastatin was associated with the largest risk reduction, whereas 
fluvastatin and lovastatin had no protective effects. (3) Statin exposure duration was inversely 
associated with the risk of non-vascular dementia. 
Atrial fibrillation and dementia 
Similar to AF, the disease burden of dementia is increasing with the ageing population . 
Non-vascular dementia, including senile dementia and Alzheimer’s disease, is the most 
common type of dementia in elderly individuals, accouting for 80–90% of cases, with the 
remainder accounted by vascular dementia.
5,19,20
 In addition to age, dementia and AF share 
some background risk factors such as hypertension, diabetes, smoking, and systemic 
inflammation.
21,22
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Recent studies have increasingly disclosed important links between AF and dementia.
2,5-
7
 In a study involving 37,025 patients, Bunch et al. found that AF was independently 
associated with all forms of dementia, including non-vascular and vascular types.
5
 A recent 
post-hoc analysis of the “ONTARGET” and “TRANSCEND” randomized controlled trials, 
which involved 31,546 patients (1,016 with AF at baseline and an additional 2,052 
participants with AF during follow up), demonstrated that AF was associated with an 
increased risk of cognitive and functional decline, and the results were consistent among 
patients with and without stroke.
6
 These previous findings suggest that the link between AF 
and dementia cannot be fully explained by cerebral infarction caused by AF-related 
thormboembolism. 
In addition to an increased risk of dementia in AF patients, the coexistence of AF and 
dementia also significanlty increases the risk of mortality.
5
 Thus, the development of an 
effective method to reduce the risk of dementia in the AF population is clinically important. 
Although two epidemiologic studies in the general population initially reported a 60% lower 
prevalence of dementia in statin users in 2000,
8,9
 several subsequent studies yielded 
inconsistent findings. Rea et al. showed that statin therapy was not associated with a 
decreased risk of dementia in a community-based cohort of 2,798 subjects aged > 65 years.
13
 
Statin therapy also failed to show benefits in preventing cognitive decline in the PROSPER 
trial.
23
 Given these conflicting results and the lack of studies focusing on patients with AF, a 
study with a larger population and longer follow-up period is needed to confirm the effects of 
statin in the prevention of dementia in these patients.  
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In the present study, we demonstrated that statins may be useful in preventing non-
vascular dementia in the AF population. To our knowledge, it is the first large-scale 
nationwide study to investigate the relationship between statin use and the risk of non-
vascular dementia, specifically in subjects with AF.  
Statins and the risk of dementia 
The mechanism(s) underlying the usefulness of statin in the prevention of dementia 
remain incompletely understood. Several previous studies showed that atherosclerosis was 
involved in the pathogenesis of not only vascular, but also non-vascular, dementia, such as 
Alzheimer’s disease, through the promotion of vascular and plaque/tangle pathologies in the 
brain.
24,25
 Thus, statins may prevent dementia via anti-atherosclerotic effects. However, as the 
endpoint of the present study was non-vascular dementia, other effects in addition to the anti-
atherosclerotic activity of statins may also be important. Statins possess anti-inflammatory 
properties and have been demonstrated to reduce high-sensitivity C-reactive protein levels.
26
 
Several recent studies have even suggested that an increased systemic inflammatory status is 
associated with accelerated cognitive decline and increased risk of dementia.
27-29
 Indeed, 
there is also plausible evidence demonstrating that inflammation plays an important role in 
the pathogenesis of AF.
30,31
 Accordingly, the use of statins may protect patients with AF from 
dementia by reducing systemic inflammation.     
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Clinical implications 
The present study shows that statins may be able to prevent non-vascular dementia in 
patients with AF. The protective effects of statin use were consistently observed in subgroup 
analyses based on patients’ comorbidities and medications. A lower risk of non-vascular 
dementia was still observed in patients receiving statin treatment compared to matched 
controls. Use of more potent statins, such as rosuvastatin, atorvastatin and simvastatin, and 
longer exposure time were associated with an even greater risk reduction in dementia. One 
exception was pravastatin which exhibited a more obvious protective effect than atorvastatin 
and simvastatin. However, pravastatin may have different effects from simvastatin on the 
level of lipoprotein in the cerebrospinal fluid and the expression of dementia-related genes in 
human astrocytes and neuronal cells.
32,33
 However, the precise mechanisms behind the 
obvious effects of pravastatin in reducing non-vascular dementia were unclear, and the data 
presented here should be interpreted carefully and further confirmed. Taking these findings 
together, statins should be considered as a potential treatment for patients with AF aged > 60 
years to prevent non-vascular dementia in addition to lowering lipid levels.  
Study limitations 
The strengths of our study include the use of a nationwide dataset, which contained data 
from a large sample of AF subjects and enabled the continuous tracing of dementia risk in 
statin users and non-users. However, our study has several important limitations. First, while 
we reported the significant association between non-vascular dementia and statin use, these 
results were derived from an observational database. Therefore, we were not able to conclude 
that statins had directly protective effects against dementia, and only a prospective and 
randomized trial can answer the question. Second, the diagnosis of dementia was based on 
the diagnostic codes registered by the physicians responsible for the treatments of patients, 
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and data about the degree and severity of cognitive impairment were lacking. Third, we 
defined study endpoint as “non-vascular dementia” and excluded “vascular dementia” using 
the ICD-9 codes. Therefore, the under recognition of the vascular factors which could cause 
dementia is possible. However, we have tried to minimize the possibility of misclassification 
of non-vascular dementia using subgroup and sensitivity analyses. Fourth, multiple baseline 
characteristics differed between the statin and control groups, as the present study was not a 
prospective trial. However, age, gender, and CHA2DS2-VASc score were matched between 
these two groups, and the reliability of our findings was further supported by the observed 
inverse relationship between statin exposure duration and the risk of non-vascular dementia. 
Lastly, the detailed information about the dose optimization and compliances of statins and 
other medications was not available in this registry database.   
Conclusion 
In this large-scale cohort study, statin use was associated with a 17% reduction in the 
risk of non-vascular dementia among patients with AF aged ≥ 60 years. Use of more potent 
statin and longer exposure time resulted in greater benefits. A prospective randomized trial is 
needed to confirm these findings. 
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Table 1 Baseline characteristics of the subjects 
Variables 
Statin group 
(n=51,253) 
Control group  
 (n=205,012) 
P value 
Age, years 73.2 ± 7.4 73.2 ± 7.4 0.999 
Age > 65 years, n (%) 44,068 (86.0) 176,272 (86.0) 1 
Gender (male), n (%) 25,490 (49.0) 101,960 (49.0) 1 
CHA2DS2-VASc score, median 
(inter-quartile range) 
5 (4-6) 5 (4-6) 1 
AF duration, years 2.01 ± 2.47 2.09 ± 2.42 <0.001 
Medical history (components of CHA2DS2-VASc score) 
    Hypertension 46,337 (90.4) 190,622 (93.0) <0.001 
    Diabetes mellitus 25,091 (49.0) 98,564 (48.1) <0.001 
    Congestive heart failure 25,749 (50.2) 109,528 (53.4) <0.001 
Previous stroke/TIA 24,444 (47.7) 98,044 (47.8) 0.596 
Previous vascular diseases 26,610 (51.9) 95,998 (46.8) <0.001 
Medical history 
End-stage renal disease 1,095 (2.1) 2,633 (1.3) <0.001 
COPD 4,944 (9.6) 19,087 (9.3) 0.020 
Malignancy 2,859 (5.6) 11,597 (5.7) 0.491 
    Autoimmune diseases 1,351 (2.6) 4,608 (2.2) <0.001 
    Thyroid diseases 1,567 (3.1) 5,278 (2.6) <0.001 
    Liver cirrhosis 743 (1.4) 5,258 (2.6) <0.001 
    Sleep apnea 908 (1.8) 3,319 (1.6) 0.015 
Medications     
    Aspirin 24,521 (47.8) 81,145 (39.6) <0.001 
    Clopidogrel 5,409 (10.6) 100,81 (4.9) <0.001 
    Warfarin 6,752 (13.2) 23,274 (11.4) <0.001 
    Digoxin 11,935 (23.2) 52,131 (25.4) <0.001 
    ACEIs/ARBs 20,330 (39.7) 69,531 (33.9) <0.001 
 
ACE = angiotensin-converting enzyme inhibitor; ARB = angiotensin II-receptor blocker; 
COPD = chronic obstructive pulmonary disease; TIA = transient ischemic attack. 
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Table 2 Incidence (per 100 person-years) of non-vascular dementia in patients with and 
without statin use 
 
Groups Number of events Number of Patients Person-years Incidence* 
Statin 3,342 51,253 177,271 1.89 
Control  13,859 205,012 630,737 2.20 
 
*Number of ischemic strokes per 100 person-years of follow-up 
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Table 3 Cox regression models on the relationship between stain use and risk of non-vascular 
dementia 
 
 
ACE = angiotensin-converting enzyme inhibitor; ARB = angiotensin II-receptor blocker; CI 
= confidence interval; COPD = chronic obstructive pulmonary disease; HR = hazard ratio 
Models 
HR 
(statin versus 
control group) 
95% CI P value 
Model 1: unadjusted regression analysis 
 
0.856 0.824-0.889 <0.001 
Model 2: adjusted for age, gender 
 
0.835 0.804-0.867 <0.001 
Model 3: adjusted for age, gender and CHA2DS2-VASc score 
 
0.828 0.797-0.860 <0.001 
Model 4: adjusted for age, gender, CHA2DS2-VASc score and 
AF duration 
0.826 0.795-0.858 <0.001 
Model 5: adjusted age, gender, AF duration, hypertension, 
diabetes mellitus, heart failure, vascular diseases,  end-stage 
renal disease, COPD, autoimmune diseases, thyroid diseases, 
liver cirrhosis and sleep apnea 
 
0.829 0.798-0.861 <0.001 
Model 6: adjusted for all variables in model 5, and the use of 
aspirin, clopidogrel, warfarin, digoxin and ACEI/ARB 
 
0.832 0.801-0.864 <0.001 
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 Figure Legends 
Figure 1 Statin use and the risk of dementia. Kaplan–Meier survival analysis showed that 
statin use was associated with a lower risk of dementia during the follow-up period. 
Figure 2 Statin use and the risk of dementia in different groups of patients. In the 
subgroup analysis, statin use was consistently associated with a lower risk of dementia in 
different groups of patients. *Adjustment for age, gender, AF duration, hypertension, diabetes 
mellitus, heart failure, vascular diseases, end-stage renal disease, COPD, autoimmune 
diseases, thyroid diseases, liver cirrhosis, sleep apnea and the use of aspirin, clopidogrel, 
warfarin, digoxin and ACEI/ARB. ACE = angiotensin-converting enzyme inhibitor; ARB = 
angiotensin II-receptor blocker; CI = confidence interval; COPD = chronic obstructive 
pulmonary disease; HR = hazard ratio; TIA = transient ischemic attack. 
Figure 3 Types of statin, exposure duration, and the risk of dementia. (A) Rosuvastatin 
was associated with the lowest risk of dementia compared with statin non-users. Conversely, 
fluvastatin and lovastatin did not significantly protect patients with AF from dementia. (B) 
Among statin users, a longer duration of statin exposure was associated with a lower risk of 
dementia. *Adjustment for the same variables in Figure 2.Abbreviations as in Figure 2. 
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